Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 9;14:931–940. doi: 10.2147/JPR.S297442

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Shang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

ERK1/2 was involved in the process of estrogen down-regulating NGF expression and release. (A) Protein was isolated from estrogen-treated chondrocytes, and p-ERK content was analyzed by WB, emerging a higher level than non-treated group. (B) WB results were quantified and presented in column graph style. Difference between two groups were seen clearly. (C) NGF mRNA expression in cultured with PD increased to 1.41Ct (2.07±0.1 fold) than non-treated. Estrogen-decreased NGF level was inhibited by PD. (D) NGF protein release paralleled with mRNA tendency. All data were shown as mean ± SEM from three independent experiments.

Notes: *P <0.05, **P <0.01.

Abbreviations: ELISA, enzyme-linked immunosorbent assay; NGF, nerve growth factor; WB, Western blotting; PD, PD98059.